All In MedTech

Device Trial Radar · NCT04261686

Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

A Prospective, Multi-Center, Non-Randomized Clinical Study of the BARD® COVERA Arteriovenous (AV) Stent Graft in the Treatment of Stenosis in the Venous Outflow of AV Fistula Access Circuits (AVeNEW) Post Approval Study

Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

100

Actual

Start

Jul 3, 2020

Primary completion

Sep 16, 2025

Study completion Sep 16, 2025

Sponsor

Lead sponsor
C. R. BardPublic (BDX)
Sponsor type
Industry
First posted
Feb 10, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to collect post-market, real-world safety and effectiveness data of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit.

Conditions

  • Arteriovenous Fistula

Interventions

  • Covera Vascular Covered StentDevice

    This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety through 30 daysTime frame: Through 30 days following index procedure

10 more outcomes with a free account

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Kidney Disease and Hypertension Center Medical Research Services

    Phoenix, Arizona

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.